Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Miriam Hospital
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Status: Enrolling
Updated:  11/25/2015
City of Hope Medical Center
mi
from
Duarte, CA
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Status: Enrolling
Updated: 11/25/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)
Status: Enrolling
Updated:  11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)
Status: Enrolling
Updated: 11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis
Status: Enrolling
Updated:  11/25/2015
The Mayo Clinic
mi
from
Rochester, MN
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis
Status: Enrolling
Updated: 11/25/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Repeat Intranodal Injections of Ad-ISF35
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Status: Enrolling
Updated:  11/30/2015
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Study of Repeat Intranodal Injections of Ad-ISF35
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Status: Enrolling
Updated: 11/30/2015
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated:  11/30/2015
Mayo Clinic Scottsdale AZ
mi
from
Scottsdale, AZ
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated: 11/30/2015
Mayo Clinic Scottsdale AZ
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated:  11/30/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated: 11/30/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Emory University Hospital
mi
from
Atlanta, GA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  11/30/2015
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 11/30/2015
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2015
Tufts Medical Center
mi
from
Boston, MA
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2015
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Click here to add this to my saved trials
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias
Status: Enrolling
Updated:  12/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias
Status: Enrolling
Updated: 12/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures
Status: Enrolling
Updated:  12/3/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures
Status: Enrolling
Updated: 12/3/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age
Status: Enrolling
Updated:  12/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age
Status: Enrolling
Updated: 12/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  12/3/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 12/3/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  12/3/2015
Vanderbilt University
mi
from
Nashville, TN
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 12/3/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma
Status: Enrolling
Updated:  12/3/2015
Veteran's Administration Medical Center
mi
from
Las Angeles, CA
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma
Status: Enrolling
Updated: 12/3/2015
Veteran's Administration Medical Center
mi
from
Las Angeles, CA
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Weill-Cornell Medical College
mi
from
New York, NY
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/4/2015
UCSD Medical Center
mi
from
La Jolla, CA
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/4/2015
UCSD Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia
Status: Enrolling
Updated:  12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia
Status: Enrolling
Updated: 12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/8/2015
University of Iowa Hospitals
mi
from
Iowa City, IA
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/8/2015
University of Iowa Hospitals
mi
from
Iowa City, IA
Click here to add this to my saved trials
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated:  12/8/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated: 12/8/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials